Orange Biomed ’s Post

Day 1 of the #DiabetesTechnologyMeeting has officially kicked off! Stop by Orange Biomed 's abstract presentation, “Implementing a stiffness measurement of red blood cells to predict HbA1c” TODAY from 4:30 - 6:30 p.m. to find out how we are changing the diabetes care landscape with our revolutionary A1C testing method. #DTM2024

A recent study led by Erik Hong and Logan Froese explores the critical thresholds of the Long-Pressure Reactivity Index (LPRx) and its impact on intracranial pressure monitoring in TBI patients. The research, which included 435 patients, reveals that LPRx, even when calculated with lower resolution data, can be an effective substitute for the traditional PRx in predicting patient outcomes. This could broaden the scope of effective TBI monitoring, especially in settings where high-resolution data isn't feasible. Key findings: - LPRx calculated over 10–120 minutes shows similar predictive capabilities to PRx. - Both intraparenchymal and external ventricular drain methods provide comparable LPRx outcomes. - Early monitoring (first 4 days) is crucial for accurate outcome prediction. As someone deeply passionate about neuromonitoring, I find these advancements in TBI care particularly exciting. This work opens new doors for more accessible and cost-effective patient care worldwide. #TBI #NeuroMonitoring #CriticalCare #HealthcareInnovation #MedicalResearch

📢🫀We're excited to announce that we've now successfully enrolled 1000 participants into our AccessCMD Cardiometabolic Disease Cohort Study, just 2 months after study launch. The growth of AccessCMD within this time frame highlights the capability of uMed's unique approach of patient identification and tailored engagement to rapidly build a database of pre-consented patients with specific disease areas. How does AccessCMD differ from other databases? Unlike traditional registries that are static and do not easily allow for the generation of custom data, AccessCMD combines routinely collected EMR data with outcomes collected directly from patients at-home, including genetic tests, wearable device data and clinically validated scales... ✅ providing researchers with a rich source of regulatory grade data that can be further augmented with the collection of custom endpoints to meet specific research criteria ✅ AND enabling the running of standalone studies within the infrastructure of the existing cohort Find out more about AccessCMD and uMed’s Cohort Studies here: https://lnkd.in/eAdjKZ_h #cardiometabolicresearch #diabetesresearch #cardiovasculardisease #hypertension #buildevidence

Healthcare is going portable, and Zeto is ahead of the curve. As portable ECGs revolutionize cardiac care, our remote EEG technology is doing the same for brain health, without compromising on coverage or capabilities. Accessible, portable, and ready for the future of diagnostics. Want to know more about this trend? Check out this article on the next wave of digital health by @bertalanmesko and @thefutureofdigitalhealth. #DigitalHealth #EEGInnovation #PortableHealthcare #HealthcareFuture

Check out this webinar with our staff writer Annette Boyle tomorrow on pulsed field ablation.

For #NationalPublicHealthWeek, Cardio Diagnostics is dedicated to addressing the significant challenges in cardiac care through:   - Innovation in Care: Introducing cutting-edge diagnostics that transform cardiac healthcare practices by leveraging AI and epigenetics. - Early Detection: Utilizing these innovative tools to enable early identification of cardiovascular risks, setting the stage for life-saving interventions. - Precision Medicine: Bringing precision to cardiac care by tailoring diagnostics, prevention and treatment to a patient's biology, ensuring personalized care. - Proactive Approach: This approach shifts the paradigm from reactive treatment to proactive management of heart health, focusing on prevention and early intervention. - Empowering Healthcare Professionals: Providing medical professionals with the tools and insights needed for more effective and efficient patient care. Cardio Diagnostics Holdings Inc. aims to transform cardiac care and improve public health outcomes by addressing these key areas. Together, we can revolutionize the approach to cardiovascular health and make a lasting impact on the well-being of individuals and communities. #publichealth #heartdisease

ISS Medical will be be showcasing our cutting-edge biomedical instrumentation at MEDICA 2024 in Düsseldorf, Germany! Join us from November 11th-14th at booth 15F02-1, where we are proud to co-exhibit as part of the State of Illinois pavilion. We can’t wait to connect with you at MEDICA 2024! See you at booth 15F02-1! Chronic diseases such as diabetes, chronic kidney disease (CKD), and peripheral vascular disease (PVD) represent some of the most persistent challenges in contemporary healthcare. These conditions not only impose significant burdens on patients' quality of life but also drive increased rates of hospitalization, disability, and mortality. In addressing these complex diseases, early detection, real-time monitoring, and personalized treatment strategies are crucial to improving outcomes. One of the key factors common to all three conditions is compromised oxygenation in tissues, which often correlates with disease severity and progression. The ISS OxiplexTS200 tissue oximeter represents a breakthrough in non-invasive medical technology, offering clinicians a powerful tool for monitoring tissue oxygenation levels in real time. Its applications span across multiple disease states, providing valuable insights into disease management and allowing for more informed clinical decision-making. Find out more here: https://lnkd.in/gdDtjzzp #ChronicDiseaseManagement #DiabetesCare #CKD #PeripheralVascularDisease #HealthcareInnovation #ImprovingPatientOutcomes #MedicalBreakthrough #TissueOxygenation #RealTimeMonitoring #NonInvasiveTech #OxiplexTS200 #MedTechSolutions #EarlyDetection #BetterHealthOutcomes #PatientCareAdvancements #HealthcareSolutions #ClinicalDecisionSupport #MEDICA2024

ISS Medical will be be showcasing our cutting-edge biomedical instrumentation at MEDICA 2024 in Düsseldorf, Germany! Join us from November 11th-14th at booth 15F02-1, where we are proud to co-exhibit as part of the State of Illinois pavilion. We can’t wait to connect with you at MEDICA 2024! See you at booth 15F02-1! Chronic diseases such as diabetes, chronic kidney disease (CKD), and peripheral vascular disease (PVD) represent some of the most persistent challenges in contemporary healthcare. These conditions not only impose significant burdens on patients' quality of life but also drive increased rates of hospitalization, disability, and mortality. In addressing these complex diseases, early detection, real-time monitoring, and personalized treatment strategies are crucial to improving outcomes. One of the key factors common to all three conditions is compromised oxygenation in tissues, which often correlates with disease severity and progression. The ISS OxiplexTS200 tissue oximeter represents a breakthrough in non-invasive medical technology, offering clinicians a powerful tool for monitoring tissue oxygenation levels in real time. Its applications span across multiple disease states, providing valuable insights into disease management and allowing for more informed clinical decision-making. Find out more here: https://lnkd.in/gdDtjzzp #ChronicDiseaseManagement #DiabetesCare #CKD #PeripheralVascularDisease #HealthcareInnovation #ImprovingPatientOutcomes #MedicalBreakthrough #TissueOxygenation #RealTimeMonitoring #NonInvasiveTech #OxiplexTS200 #MedTechSolutions #EarlyDetection #BetterHealthOutcomes #PatientCareAdvancements #HealthcareSolutions #ClinicalDecisionSupport #MEDICA2024

The second day of #2024NPC was packed with groundbreaking innovation and passionate advocacy. Highlighting the urgency for health policy change, Peggy Tighe and 'Skeeter' Salim (https://lnkd.in/evX7bbYn) focused on the need for the 'Improving Seniors’ Timely Access to Care Act.' Later, RaySearch Laboratories showcased the latest advancements proton planning, machine learning, and future innovations with evolving delivery systems recently featured in the AMERICAN ASSOCIATION OF MEDICAL DOSIMETRISTS journal (https://lnkd.in/gAT8bMue), demonstrating the conference's commitment to innovation. Insightful discussions on payment reforms led by experts, Drs. Hug Eugen, Sameer Keole, Arpit Chhabra, MD, and Hemant H., explored avenues to enhance accessibility. The IBA Industry Expert Theater showcased the latest in cutting edge technology, making for a day rich with learning and future-forward conversations. We're gearing up for an exciting lineup tomorrow with the Mevion Medical Systems Industry Expert Theater that will continue industry dialogue on groundbreaking proton therapy technology. The NAPT Excellence Awards will celebrate significant achievements in the field while the Ignite session promises to spark engaging discussions on the future of PT. A centerpiece of tomorrow's schedule is the 'Patient Voices: Perspectives on Patient Experience and Survivorship' session. This segment will offer a powerful platform for patient stories, shedding light on the real-world impact of proton therapy on survivorship and quality of life. #2024NPC is not just a conference, it's a community united in advancing healthcare. Thanks to exhibitors, attendees, and sponsors; your participation is crucial as we push the boundaries of cancer treatment.

Movano Evie Ring to be used in MIT Long Covid study By James Stables Despite a lukewarm reception and our own misgivings in our initial Evie Ring review, the smart ring will be used to track the vitals of patients with long COVID and chronic Lyme disease. “We’re excited to incorporate the Evie Ring into our clinical study to evaluate the progression of long COVID and chronic Lyme disease and paint a fuller picture of why some people bounce back from a mild infection while others go on to endure prolonged suffering,” said Dr Michal Caspi Tal, associate scientific director at the MIT Center for Gynepathology Research and head of the Tal Research Group, said in a statement. “The breadth of longitudinal information related to vital signs and wellness provided by the ring will be instrumental in enhancing our understanding of these debilitating conditions.” In our initial conversations with John Mastrototaro, CEO of Movano, he told Wareable that it was a key ambition of the company for Evie to be used in medical settings. While it’s still waiting for clearance, the company aims to have all of its sensors and metrics FDA cleared – even ‘basic’ ones such as heart rate and SpO2. It’s rare for device makers to go down this route because most claim that their devices are ‘not for medical use.’ We’ve recently published our early Movano Evie Ring, which has been beset by technical issues and complaints around the basic nature of the features and insights. But MIT selecting Evie is a vote of confidence in the accuracy of its sensors, which has not been a cause for concern. Our criticisms of the ring stemmed from reliability issues, and the basic nature of its insights. It also validates Movano’s strategy for Evie to be used outside of the consumer setting. Success in this area will enable the company to keep offering the ring without a subscription, and keep prices down. Now it just needs to hunker down and ensure that its consumer experience can rival the likes of Oura. Posted by Larry Cole - my usual disclaimers at in play here. I was not asked to post this MIT piece, nor do I know anyone at Movano. I do these as public interest stories more than anything else. If you follow my posts you will already know I am a big believer in wearables fundementally changing how we deliver healthcare to the masses.